PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: PF-07242813Drug: Placebo
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT04668066
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸Keck School of Medicine of USC, Los Angeles, California, United States
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
- Conditions
- Atopic DermatitisPlaque Psoriasis
- Interventions
- Drug: PF-07038124 ointmentDrug: Vehicle ointment
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT04664153
- Locations
- 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇵🇱Mazowieckie Centrum Badań Klinicznych, Grodzisk Mazowiecki, Poland
🇵🇱Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 258
- Registration Number
- NCT04657991
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Germany
🇺🇸UCLA - Hematology/Oncology - Administrative Office, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug, Los Angeles, California, United States
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04655040
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Swedish Ibrance Registries Insights (SIRI)
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1500
- Registration Number
- NCT04654208
- Locations
- 🇸🇪
Pfizer AB, Sollentuna, Sweden
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Conditions
- Pediatric Migraine
- Interventions
- Drug: Rimegepant/BHV3000Drug: Matching placebo
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2100
- Registration Number
- NCT04649242
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Research Institute, Miami, Florida, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Accel Research Sites-Neurology and Neurodiagnostics of Alabama, LLC, Birmingham, Alabama, United States
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT04649359
- Locations
- 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇱Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
- Conditions
- Tick-Borne Encephalitis
- Interventions
- Biological: TBE vaccine 0.25 mLBiological: TBE vaccine 0.5 mL
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 165
- Registration Number
- NCT04648241
- Locations
- 🇯🇵
Ohigesenseino Kodomo Clinic, Sapporo, Hokkaido, Japan
🇯🇵Medical Co. LTA PS Clinic, Fukuoka,, Fukuoka, Japan
🇯🇵Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Conditions
- ALK-positive NSCLC
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 549
- Registration Number
- NCT04647110
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
- Conditions
- Meningococcal Vaccine
- Interventions
- Biological: MenABCWYBiological: Bivalent rLP2086 (60-µg Dose)Biological: BexseroBiological: Bivalent rLP2086 (120-µg Dose)Drug: Prophylactic Liquid Paracetamol (PLP)Other: PlaceboBiological: NimenrixDrug: Therapeutic Liquid Paracetamol (TLP)Drug: Scheduled Liquid Paracetamol (SLP)
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 326
- Registration Number
- NCT04645966
- Locations
- 🇬🇷
P. & A. Kyriakou Children's Hospital, Athens, Greece
🇩🇪Dr. med Falko Panzer Praxis fuer Kinder und Jugendliche, Mannheim, Germany
🇬🇷University General Hospital "ATTIKON", Athens, Greece